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ABSTRACT

Warfarin is widely used oral anticoagulant and its pharrnacokinetic (PK) and
pharrnacodynamic (PD) properties have been extensively studied. It has a narrow
therapeutic index and displays poor quality of treatment due to its complex pharmacology
and wide inter and intraindividual variability in the dose-response relationship.

This study developed an integrated PK-PD model using STELLA® to describe the doseconcentration-effect relationship for warfarin. This model used previously reported
population PK and PD models and parameter values to generate dose-response data. A
one compartment stereo-specific semi-physiological PK model with zero-order drug
input was linked to an indirect PD model describing the anticoagulant effect. The indirect

(

PD model consisted of two components: (i) the plasma concentration of S-enantiomer of
warfarin (Cs) was related to synthesis of prothrombin complex activity (PCA) described
by sigmoid Imax model (ii) conversion of PCA to prothrombin time ratio (PTR), which is
further standardized in terms of INR. The model was used to study the manner in which
the interindividual variability in fundamental PK parameters (intrinsic clearance, protein
binding affinity constant and protein concentration), PD parameters (potency and
sigmoidicity) and intraindividual variability in dose affect warfarin response. For each
condition of interindividual variability studied, 100 sets of PK and PD response data were
collected and % coefficient of variation (CV) was calculated. For each condition of
intraindividual variability studied, 2000 data sets of PD response were collected and %
CV was calculated.
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For the model used in this study, variability in the response to warfarin was least sensitive
to interindividual variability in protein binding affinity constant of S-warfarin (Ka_s),
protein concentration (P) & sigmoidicity (Y) and also to intraindividual variability in
dose. The PK and PD response was found to be most sensitive to interindividual
variability in intrinsic clearance of S-enantiomer (CLint_s) and potency (IC 5o) parameters.
Clinically, these parameters are important and their variability in population must be
taken into account in order to optimize the dose and use the drug effectively and safely.
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PREFACE

This thesis has been written in the non-manuscript format option as per the guidelines
issued by the Graduate School, University of Rhode Island.

Contained within is a main body of work presented as individual chapters (Introduction,
Methodology, Results, Discussion and Conclusions) followed by the Appendices
(ancillary data and other details pertinent to the understanding of the concepts presented
in the manuscript). This thesis closes with the complete listing of all the works cited in
this thesis, arranged in alphabetical order by the author' s last name.
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1. INTRODUCTION

The relationship between dose and response is the cornerstone of drug therapy.
Traditional PK models alone have limited applicability in understanding complete doseresponse relationship for drugs that do not have direct linear relationship between drug
concentration and therapeutic effect. For such drugs, thorough understanding of all of the
individual processes involved from the time the dose is administered to the appearance of
the clinically observed effect is very important. Overall, the intensity and duration of
response to a given dose of a therapeutic drug can be considered as a function of two
sequential phases: PK phase and PD phase. The PK phase describes the drug
concentration-time course m body fluids (often plasma/ serum) resulting from
administration of a certain dose of a drug. The PD phase, on the other hand, relates
observed effect to the concentration of drug at the "effect site".

1.1. Pharmacokinetic Models:

PK models, which incorporate the rate processes of distribution, metabolism and
elimination as well as absorption in the case of orally administered drugs, are derived
from concentration time data. The models can then be used to observe the system under a
variety of conditions. Often the PK phase is linear and as a result the dose concentration
relationship is fairly predictable. Critical PK parameters that are used to describe the PK
processes include volume of distribution and clearance. For orally administered drugs,
additional PK parameters include absorption rate and bioavailability. The number of
parameters required to describe the dose-concentration relationship depends on the
complexity of the process and on the route of administration.

Over the last two decades the knowledge of pharmacokinetics has increased greatly and a
variety of mathematical models and software have been successfully developed. The
pharmacokinetics of most of the drugs and the factors influencing the PK processes are
well understood and documented.

1.2. Pharmacodynamic Models:

PD models are used to characterize the relationship between drug concentrations at the
site of action and the pharmacological effect

(I)

and are used to develop mathematical

expressions to describe the drug response as a function of the concentration time profile.
Although the concentration at the receptor site drives the response, owing to the
difficulties associated with measuring this value, plasma concentrations are usually used
for PD models in vivo. Critical PD parameters include efficacy (Emaxllmax), potency
(EC 50/IC 50) and sigmoidicity (Y). The efficacy represents the maximum effect that occurs
when all the receptors are occupied. The potency is the concentration at 50% of the
maximum effect and Y is the number of drug molecules bound to each receptor and it
determines the steepness of the concentration-effect relationship. If the drug has
stimulatory action the PD parameters are Emax and EC 5o and if the drug has inhibitory
action, Imax and IC 5o are used to represent efficacy and potency respectively. When the
PK steady-state conditions exist and the pharmacological effect is easily measured,
concentration-effect relationships can be described by simple PD models such as fixed
effect model, linear model, log-linear model, Emax-model, and sigmoid Emax-model

1
<

>.

The selection of model basically depends on many factors such as (a) the drug used (b)
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the response to be measured (c) the effect observed after administration of drug and of
placebo (d) the degree of linearity in the effect-concentration curve (e) potential for
achieving the maximum possible response. However, the non-linear Emax and sigmoid

Emax models are very commonly used to describe the PDs of many drugs. The sigmoid
Emax model is a modification of the Emax model, which accounts for the probability that
more than one drug molecule binds to each receptor by using the term sigmoidicity (f).
The sigmoid Emax model is derived from the Hill equation <2>. In some cases, additional
components are required to accommodate distribution lag times and/or indirect drug
effects, which often complicate the concentration-response relationship. In the case of a
distributional delay (3>, plasma concentration Vs effect plots indicate pronounced
hysteresis. Such relationship can be simplified by considering hypothetical effect
compartment to account for the time lag between concentration and response

4
(t ,

>, and

using steady-state conditions. Owing to the complex and non-linear nature of the plasma
concentration-effect relationships, it is often difficult to predict how the system may
behave under a variety of situations. Thus, simulation studies can be very valuable.

The PDs of relatively few drugs has been extensively studied due to the difficulty in
measuring clinically relevant responses. In the absence of PD information it is difficult to
appreciate and understand the impact of altered PKs on the drug response.

1.3. Combined Pharmacokinetic-Pharmacodynamic models to understand the doseresponse relationships:

3
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In understanding dose-response relationships, an integrated approach involving combined
pharmacokinetic and pharmacodynamic modeling has proved tremendously helpful

56 1
<• •
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The objective for PK-PD modeling is to link PK and PD phases of the drug to establish
and evaluate dose-concentration-response relationships and subsequently describe and
predict the effect-time courses resulting from given dose of drug. In general, PK-PD
modeling based on the underlying physiological process should be preferred whenever
possible

5

<

>. This approach has provided significant insight into the pharmacology of

various drugs under conditions of normal and abnormal physiology. Furthermore, to
characterize and appropriately describe the time course of drug action under non steadystate conditions, PKs and PDs of the drug have to be adequately linked to predict doseconcentration relationship and concentration-effect relationship. This link can be
established, when the plasma concentration is substituted for concentration in PD
equations with an assumption that the concentration at the site of action is in equilibrium
with plasma. This assumption may be valid, if the drug effect is direct, receptor site
rapidly equilibrates with plasma and the drug-receptor interaction in relation to the
response occurs rapidly.

The direct correlation of pharmacological response to drug concentration is not always
possible with all drugs. Sometimes intermediate steps are involved in the mechanism of
action of the drug that is more complex than is assumed in the model. For example, doseresponse relationships can be complicated when the drug action is indirect and/or
irreversible. Four basic physiologic indirect response models proposed by Jusko et al.
may be used in PK-PD modeling to describe the pharmacodynamics of drugs that have

4

indirect mechanisms such as inhibition/stimulation of the production or degradation of

(
endogenous substances/mediators, which control the measured response cs, 9• IO) . These PD
models when coupled with the PK models of the drug help in simplifying the relationship
between the dose administered and the clinically observed response. For example,
warfarin (anticoagulant) exerts an indirect action and the resultant delay in response
makes a direct correlation of the anticoagulant activity to the plasma drug concentration
impossible. Therefore, plasma warfarin level is correlated with inhibition of the
prothrombin complex production rate, which is then linked to the pharmacological
response (anticoagulation). The application of PK-PD modeling to understand doseresponse relationship in the case of warfarin is described in detail in the following
sections of this thesis.

1.4. Sources of Variability

Biological variability is an inherent feature of drug action. Variability in a response arises
in drug therapy when a standard dose or dosing regimen evokes differing responses in
various individuals (referred to as interindividual variability) or in a given individual at
different times (referred to as intraindividual variability). However, interindividual
variability was identified to be major source of variability for many drugs

Cl I).

Intra and interindividual variability in the dose response relationship can arise from two
sources: PK variability and PD variability. Clinically, PK variability commonly arises
from variability in the PK parameters describing the rate and extent of absorption,
distribution, metabolism, and elimination of drugs. Some drugs show greater

5

pharmacokinetic variability than others do. Variability in the PK characteristics of drug is
well recognized and understood due to the ease of monitoring and control of therapeutic
plasma concentrations. But, little is known about PD variability due to the difficulty of
measuring clinically relevant responses for most drugs and limited research activity in
this field <11 >. The other reason for poor understanding of PD variability is because of
difficulty in distinguishing between PD and PK variability. For example, if a certain
pharmacologic effects arises, wholly or in part, from a minor metabolite of a drug, then a
twofold or threefold increase in the formation of that metabolite could cause a substantial
increase in pharmacologic effect without any apparent change in the drug's PKs. The
increased pharmacological effect may be interpreted as due to PD rather than PK
variability if the role of the quantitatively minor metabolite has not been recognized

12
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The magnitude of variability in the PK and PD parameters may be of varying amounts
depending on the drug and the pathological condition of the patient. Over the last decade
enormous work have been done to understand PK and PD variability and the factors
influencing this variability. Factors such as age

3 13 14
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<•

>, gender

3 13 15
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<•

nutrition, genetics, environment, and concurrent drug therapy <6•

16
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>, disease state,

may affect the

patient's physiologic functions and lead to variation in the pharmacokinetic and/or
pharmacodynamic parameters.

The interindividual differences in the relationship between drug plasma concentration and
pharmacological effect intensity have been reported to be mainly due to various factors.
These factors include: (i) receptor density and affinity (ii) the formation and elimination
kinetics of endogenous ligands (iii) postreceptor transduction processes (iv) homeostatic

6

responses and (v) the kinetic characteristics of transporters involved in drug transfer

(
between fluids of distribution and the biophase <11 >. Usually PD variability is more
pronounced than PK variability. Mandema et al. reported large interindividual PD
variability in response as compared to interindividual PK variability in the case of
ketoro lac <17>.

1.5. Warfarin

Warfarin, the most commonly used anticoagulant, is an example of a drug that displays
wide-variability in the dose-response relationship in the population (6,

7 18 22 23
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>. Since

both sub-therapeutic and large doses are associated with serious clinical consequences
24

<

>, the PK and PD of warfarin have been extensively studied. These studies have been

conducted in order to provide insight into dose optimization and identification of factors
that influence dose-response relationship. Additionally, since the effect of warfarin is
easily measured, there is much information in the literature on pharmacodynamics of
warfarin.

Warfarin is administered clinically as a racemic mixture of two enantiomers, R- and Swarfarin. The disposition and pharmacological action of the both the enantiomers are
qualitatively similar but quantitatively quite different

25

<

>. The differences in the

anticoagulant activities and metabolism of the S- and R- isomers of warfarin are very
large. As a result, it is necessary to consider these isomers separately in PK & PD model
for warfarin.

7

1.5.1. Pharmacokinetics
(

The pharmacokinetics of warfarin has been extensively studied, and several reviews of
warfarin pharmacokinetics have been published

2 21
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Warfarin is rapidly and

completely absorbed from the gastrointestinal tract. Warfarin does not exhibit dose
dependency in the rate or extent of absorption, and enantiomer specific differences in
absorption patterns have not been reported. Warfarin is highly plasma protein bound drug
and binds to albumin at site I. The bound fraction of racemic warfarin ranged from 97.4
to 99.9% under normal physiological conditions (6,

28

>. In early 1975, Yacobi et al

demonstrated significant intersubject variability in the extent of protein binding at
therapeutic concentrations; intrasubject variability was much less substantial <29>.
Variations in albumin concentrations in plasma occur as result of altered synthesis, loss,
or a shift of albumin from the intravascular to extravascular spaces. Physiologic
conditions such as age, pregnancy, and nutritional status cause decrease in albumin
concentration

30
< >.

Pathologic conditions include renal disease, hepatic disease, acute

myocardial infraction, cancer, sever bum injury, diabetes mellitus, thyroid disease, and
cystic fibrosis lead to decreased plasma protein binding due to altered protein
concentrations, or qualitative changes in protein molecules

30
< >.

Concurrent administration

of warfarin with other highly protein bound drugs having affinity to site I on albumin
may lead to changes in binding of warfarin. The principal route of warfarin elimination is
hepatic metabolism and renal excretion was reported to be very negligible

31

<

>. The

metabolic elimination of the pharmacologically more potent S-enantiomer is mediated by
cytochrome P450 CYP2C9 isoform which steroselectively converts S-warfarin to the
inactive phenolic metabolite, S-7-hydroxywarfarin. The rate of elimination of the two

8
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isomers differs substantially. Warfarin undergoes restrictive hepatic clearance <32>. Thus
its clearance is approximated by the following equation:
(1)

Where,
CLtt is the Hepatic clearance of warfarin;
CLint is the Intrinsic clearance of warfarin; and
fu is the fraction of warfarin unbound to plasma proteins;
It can be seen from equation (1), an increase in "free" fraction in an individual would
lead to a substantial increase in hepatic clearance and thus total body clearance. The
variations in intrinsic clearance of warfarin are usually associated to interindividual
differences in the activity of the drug metabolizing enzyme systems due to genetic and
environmental effects. The hepatic metabolism was reported to be the major determinant
of intrasubject variability in the warfarin dose-concentration-response relationship.

1.5.2. Pharmacodynamics

Unlike the direct concentration-effect relationships identified for most drugs, the
relationship between warfarin's anticoagulant effect and the drug's concentration in
serum or plasma is nonlinear, complex and indirect. The anticoagulant action of warfarin
is mediated by inhibition of vitamin K reductase linked to the vitamin-K dependent
carboxylation of glutamic acid residues on certain coagulation proteins like prothrombin,
clotting factors II, VII, IX, X and protein C <33). The overall effect can be characterized in
terms of the degree of inhibition of the synthesis rate of prothrombin-complex activity

9
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(PCA). The reduction in the activity of these clotting factors results in a prolongation of
clotting time, an effect easily measured clinically.

Warfarin is administered as a mixture of R- and S- enantiomer. However, the
anticoagulant activity of the S-enantiomer has been reported to be 3 to 6 times as greater
as that of the R-enantiomer

34
< >_

The pharmacodynamics of warfarin have been described

using a mechanism-based indirect model

2 10 33
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•
>_

This consists of a sub-model for

synthesis and degradation of clotting factors, and the inhibitory action of warfarin on
clotting factors synthesis. Changes in the amount of clotting factors alter the PCA, which
can be clinically assessed using prothrombin clotting time (PT). Owing to the
dependency of the PT on the particular thromboplastin used in the test an additional
thromboplastin-specific parameter, International Sensitivity Index (ISI), is required to
relate a thromboplastin dependent PT to the standardized international normalized ratio
(INR)

35 36 37
< • •

>. Although the INR system is unreliable during the initiation of warfarin

therapy, it does provide an advantage over the reporting of the results as PT ratio

36 38
< •

>.

Thomas et al. indicated that oral anticoagulant therapy monitored with the INR is
associated with lower bleeding complications than therapy monitored with the PT ratio,
and the rate ofthromboembolic events using the INR is acceptably low <39>_

Factors that have been reported to influence sensitivity to warfarin include (i) disease
conditions: congestive heart failure
insufficiency

42
< >

25
<

>, thyroid disease

40
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(ii) age

41
< >

(iii) hepatic

(iv) differences in the hemostatic response to given concentrations of

warfarin and (v) concomitant administration of other drugs <20>. Factors that influence

JO

(

warfarin resistance include (i) Patient non-compliance (ii) Excessive intake of vitamin K
(iii) Co-administration with other drugs that induces cytochrome P450 2C9 enzyme
system and (vi) hereditary resistance which may require increased doses of warfarin <43 • 44•
45)

Several approaches have been proposed in the literature to describe the anticoagulant
response of warfarin using a combined pharmacokinetic-pharmacodynamic model

(2).

However, previous attempts have not considered the warfarin anticoagulant response in
terms of INR. In the present study, INR component was considered in the integrated PKPD model to report the pharmacodynamic effects of warfarin.

The effect of variability in PK parameters and PD parameters play an important role in
causing the variability in therapeutic response among population. Therefore, these
simulation studies were conducted to compare the individual and combined effect of PK
and/or PD parameters of warfarin on PK response data from a one compartment model
with zero order absorption and PD response arising from an indirect sigmoid Imax model.

The objectives ofthis study include:
I.

To create an integrated PK-PD model for warfarin that takes into account individual
enantiomers of warfarin. The model developed in STELLA® use average population
values of the parameters from previous investigations (6, 7)_ PK model includes a submode! for clearance based on well-stirred venous equilibrium component. This submode! helps in understanding the effect of parameters such as fraction of S-warfarin

11

bound to plasma proteins and intrinsi9 clearance of S-enantiomer (CLint_s) on plasma

(

concentration of S-enantiomer (Cs) and anticoagulant effect of warfarin in terms of
INR.
2.

Perform computer simulations:
(i). To evaluate and compare the manner in which different sources of variability in
PK parameters such as CLint_s, protein binding affinity constant CKa_s) and plasma
albumin concentration (P) and PD parameters such as IC 5o and Y affect the doseresponse relationship of warfarin.
(ii). To investigate the relative impact of intraindividual variability in dose on Cs, and
INR.
All the simulations were performed using computerized integrated PK-PD model.

12

(

2. METHODOLOGY

The integrated PK-PD model describing the complete dose-response relationship for
warfarin was constructed in STELLA® (High Performance Systems, Hanover, NH). This
model was used throughout the study.

2.1. Pharmacokinetic Model

A one-compartment stereo-specific semi-physiological pharmacokinetic model, which
adequately describes the warfarin dose-concentration relationship, was used (6). Hignite
46

< > and

Chan

6

< > reported

that the anticoagulant activities and metabolism of warfarin

enantiomers are different in many aspects. For these reasons, the PK model in this study
took into consideration the individual isomers of warfarin as separate drugs. Constant,
zero order oral administration was used in all the simulations. The bioavailability of
warfarin was assumed to be 100%
and completely

42
< > at

2
< > and

the dose was assumed to be absorbed rapidly

a constant rate over a 24 hour dosing interval. Zero order input was

assumed in all the simulations so it would facilitate the understanding of different
sensitivity of the warfarin response to various different factors.

In 1993, Pitsiu et al. performed a population PK and PD study of warfarin in 48 normal,
healthy young volunteers <7>. Another population study was conducted by Chan et al. in
1994 <6>. The population PK and PD parameter values reported by these studies were used
in the present investigation. These parameters were chosen due to the following reasons:
the study represented an integrated PK-PD analysis and thus both PK and PD parameters
were derived in the same analysis; PK and PD data were available on both S- and R-

13
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enantiomer of warfarin and since these isomers were reported to display different
pharmacokinetics and pharmacodynamics

46 48
< •
>,

it was considered that each isomer

should be represented individually in the model; a true population approach using
NONMEM was used and the estimates were also in agreement with those reported in the
previous studies <49>,

The primary route of warfarin elimination was reported as hepatic metabolism <50>.
Hepatic clearance was calculated using the well-stirred venous equilibrium model <32>
with the equation.
CLH=E

*Q

(2) and

E = (fu * CLint) I (Q + fu * CLint)

(3)

Where,
CLH is the hepatic clearance of warfarin;
Eis the extraction ratio;
Q is the hepatic plasma flow, 40.5 L/h <51 >;
fu is the fraction of drug unbound to plasma proteins; and
CLint is the intrinsic hepatic clearance of warfarin
W arfarin was assumed to undergo first order elimination <7>. Mean population PK
parameter values obtained from the warfarin literature of Pitsiu et al. were used. The
parameter values were well in agreement with other investigations <6>. First order
elimination rate constants of S- and R- enantiomer used in the model were 0.0254 and
0.0193 h- 1 respectively. The terminal half-lives of S- and R- enantiomer were calculated
to be 27.3 and 35.9 hours respectively which means it takes about a week to reach steady-

14
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state conditions. The volume of distribution was 11.8 and 10.5 L for S- and R- warfarin
enantiomers respectively. The unbound fraction (fu) for S- and R- enantiomer of warfarin
was assumed to be 0.51 and 0.62 % respectively <6>.
Finally, intrinsic hepatic clearance of S- and R- enantiomer were calculated and set at
59.21 and 32.85 L/h respectively.

Effect of Protein Binding:
Concentration-dependent protein binding occurs with highly protein bound drugs such as
warfarin. The unbound fraction of warfarin can be mathematically described as
fu

=

1 I [l +Ka

* P]

(4)

Where,

Ka is the affinity constant for protein binding; and
P is the concentration of albumin plasma protein (6.5 * 104 Molar);
The values of affinity constants for S- and R- enantiomer were calculated using the above
equation and were initially set at 3.0 * 105 and 2.466 * 10 5 Molar- 1 respectively.

Initially, the amounts of both the warfarin enantiomers in the model were set to steady
state levels. Thus, the combined and individual enantiomer steady-state plasma
concentrations were expressed using equation
CPss =DI (CL* 't)

(5)

Where,
CPss represents the steady-state concentration of warfarin;
D is the dose of warfarin;
(

15

CL represents the total body clearance; and
i:

is the dosing interval;

2.2. Pharmacodynamic Model

The simple linear PD models that were usually used to describe the direct relationship
between plasma concentration and the response are inadequate to describe the
pharmacodynamics of warfarin. As described earlier, PDs of warfarin is best described
using an indirect inhibitory model in which, warfarin concentrations are related to
clotting factor synthesis but only indirectly related to the observed therapeutic effect
(INR). This indirect PD model consists of two sub-components:
(i). Relationship between warfarin concentration and PCA/PT
(ii). Conversion of PCA to INR

2.2.1. Relationship between warfarin concentration and PCA/PT

In this sub-component of the PD model the plasma concentration of S- enantiomer was
related to the PCA. Both synthesis and degradation of the clotting factors determine the
hypoprothrombinemic effect, yet warfarin will only affect synthesis. A physiologic effect
model describing the direct relationship between warfarin inhibition of epoxide reductase
and clotting factor synthesis as proposed by Nagashima et al. <52> was used. The
prothrombin complex activity in the plasma represents the net effect of the synthesis of
various clotting factors such as II, VII, IX, X and their normal degradation. This model
assumes time course of PCA after warfarin administration as a function of rate of

16

synthesis and degradation of clotting factors. This relationship can be mathematically
described as:
dPCA/dt = Rs - Ri

(6)

Where,
Rs is the Rate of PCA synthesis; and

Ri is the rate of PCA degradation;
The Rs and Ri values in the equation are expressed in terms of per cent of normal
activity. The rate of PCA degradation was calculated from it's first order rate of
degradation (Kct) and can be expressed as:

Ri = Kct * PCA

(7)

The effect of warfarin on PCA synthesis can be expressed in terms of its fractional effect
Rs

=

Kct

(8)

* PCAnormaI * l(t)

Under normal circumstances the system is assumed to be at steady state and PCA has its
maximum value (100 %)
Rs

=

Kct * 100%

A sigmoid Imax model

2
< • IO)

(9)
was used to relate warfarin concentrations to the inhibitory

action on PCA synthesis rate. Previous investigations <6• 7> indicated that R-enantiomer
have negligible effect on clotting factor activity that it can be neglected in the PD model.
Therefore, in this study, it was assumed that only S-enantiomer had pharmacological
activity and its concentration was linked to the PD model. The degree of inhibition of
clotting factor synthesis by S-enantiomer is expressed as:
l(t) = [1 - (C/ I (ICsor + C/))]

(10)

Which may be simplified and rewritten as
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Where,
I(t) is the inhibitory function of warfarin concentration that predicts the synthesis
rate as a percentage of the baseline value;
Cs is the plasma concentration of S-warfarin;
IC 5o is the plasma concentration of S-warfarin that produces 50% inhibition of
clotting factor synthesis; and

Y is the sigmoidicity describing the steepness of the concentration-effect curve;
As indicated before the values reported for warfarin population analysis by Pitsiu et al.
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were used for the PD and physiological model parameters. First order rate of degradation,
Kct was set at 0.094 h- 1, and the half-life of Kct was calculated to be 7.4 hours. The values
ofIC 50 and n were initially set in the model as 0.394 and 1.0 respectively (7)_

2.2.2. Conversion of PCA to INR

When monitoring treatment with warfarin, it is common practice to assess PCA by
determining PT and the therapeutic range is usually specified in terms of the prothrombin
time ratio (PTR). The PTR is the patient's PT divided by the laboratory's control or
normal PT. By using the PTR instead of PT alone, part of the technical variation in the
PT test is eliminated, since the ratio is unaffected if both the patient's and the normal PT
vary in the same proportion. The regression equation described by Chan et al.
obtained from serial dilutions of normal plasma was used to convert PCA to PTR
PTR = (426 + PCA * 7.75) I (PCA * 12)
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(12)

6

< > and

(

However, still systematic variation may be observed in PTR determinations due to the
considerable variability in the sensitivities of thromboplastin from different species,
manufacturer to manufacturer and lot to lot. As a consequence of the variability in
response of different thromboplastin reagents, PTR results are not comparable from
laboratory to laboratory without knowing the sensitivity of the thromboplastin. As a
result this variation could produce potential problems for anticoagulation control.

The need for standardizing the measurement of PTRs has long been recognized

53
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early 1980, the term INR was introduced to standardized the PTR by adjusting for
variability in thromboplastins with different sensitivities. Finally, the World Health
Organization has urged that all medical staff and health auxiliaries involved in controlling
anticoagulant treatment in patients should use the INR. INR system is based on
International Sensitivity Index (ISI) values derived from the plasma of patients stabilized
on a regimen of anticoagulant treatment for at least 6 weeks. The expression used to
convert PTR to INR can be described as
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INR = [PTR] 1s1

(13)

The INR would be equal to PTR if a thromboplastin with an ISI of unity were used in the
test. In this study, PTR was converted to INR using ISI of 2.2 since this is the estimated
ISI of the thromboplastin used by Chan et al <6• 54>.

Anticoagulation provides a striking benefit for patients whose treatment is conducted
within the recommended range of the INR, 2.0 to 3.0. In this study this range for INR
was considered as therapeutic range for reporting final anticoagulant response.

(
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2.3. Pharmacostatistical Model

I
\

2.3.1. Interindividual Variability Model
Interindividual variability in PK parameters (intrinsic clearance and protein binding
affinity constant for S-warfarin) and PD parameters (potency and sigmoidicity) were
modeled using the proportional error model

55
< )

as follows:
(14)

Where
Sj represents the estimate for a PK or PD parameter in the jth individual ;
8 m represents population mean of the PK or PD parameter; and
llej is normally distributed random variable with zero mean and variance ro 2 for
variability in PK and PD parameter;
The effect of 6 levels 10, 20, 30, 40, 50, and 60% CV of interindividual variability in
each parameter was investigated. The model use "sample and hold" set up in STELLA®
for each PK and PD parameter as shown in Figure 1b, 1c, 1d & 1e such that the
interindividual variability model cause each parameter to vary every 480 hours.

2.3.2. Intraindividual Variability Model
Intraindividual variability in dose was modeled using the proportional error model <55 ) as
follows:
(15)
Where
Dij

is the administered dose for the jth individual at time i;

Di

is the model predicted dose in /h individual at time i;
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Eij

is normally distributed random variable with zero mean and variance cr2 ; and

er, the coefficient of variation of the variability was set to 3%, 6% and 10% CV
In this model, intraindividual variability was assumed to cause the value of dose to
deviate from model predicted value by an amount that is proportional to the value of the
dose. This model use sample and hold set up as shown in Figure lg such that
intraindividual variability caused the dose to vary with new dose after every 24 hours.

2.4. Simulations

The impact of variability in the dose, PK and PD parameters on response variables was
studied using zero order drug input under steady-state conditions. When no variability
was given to the model parameters, the dose of 7mg and 9mg resulted INR value at the
lower end (2.2) and higher end (2.7) of therapeutic range, respectively. Owing to the nonlinear relationship between the dose administered and observed INR, simulations studies
for intraindividual variability in dose were carried out at the low and high end of the
therapeutic range using daily doses of 7 mg and 9mg, respectively.

For each set of model parameters in the PK variability studies, 100 replications of
response data (Cs and INR) were generated at 480 hour time point (under steady-state
conditions). For each set of model parameters in PD variability studies, 100 replications
of response data (INR) were generated at 480 hour time point (under steady-state
conditions). For the intraindividual dose variability studies, the response (Cs and INR)
was measured at every 24 hours over a 20 day period and 100 replications were
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performed giving a total of 2000 responses. In all the simulation runs the response data
was generated by numerical integration after every 0.01 h.

INR value within 2.0 to 3.0 was considered as therapeutic event. Any INR value < 2.0
was considered as sub-therapeutic event and any value >3.0 as event causing significant
risk of hemorrhage.

2.5. Data Treatment

Response data generated from the simulations as described above were imported from
STELLA® to a Microsoft Excel worksheet. The mean, standard deviation (SD), and thus
% coefficient of variance (CV) in response was determined for each of the 100 data sets

associated with a given experimental condition. The response values beyond 2.5*SD
were excluded from the analysis.

2.6. Statistical Analysis Using ANOV A:

ANOVA design provides greater opportunity to identify the significant parameters and
analyze the PK and PD interactions at different treatment combinations. In this study, 24
full factorial design was used to identify the individual PK parameters, PD parameters
and the combination of PK & PD parameters that have significant effect on the variability
in warfarin response (INR). The general linear model used for the ANOVA analysis was:

Y = Po+P1X1+P2X2+P3X3+P4N+P12X1X2+P23X2X3+P34X3N+P14X1N+P13X1X3+
P24X2N+P123X1X2X3+P234X2X3N+P134X1X3N+P1234X1X2X3N+E
Where:
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X1 = CLint_s; X2 = Ka_s; X3 = ICso; Xi= Y;
X1, X2, X3 and Xi are each of the independent variables;
X1X2, X2X3, X3Xi, X1Xi, X1X3 and X2Xi are the two-way interactions;
X1X2X3, X2X3Xi and X1X3Xi are the three-way interactions;
X1X2X3Xi is the four-way interaction;
13 0 is the overall mean;
13 1, 13 2, 13 3, 13 4 are the coefficients of factor effects;
1312, 13 23 , 1334, 1313, 13 14, 1324 are the coefficients of two-way interaction effects;
13123, 13 23 4, 13 134 are the coefficients of three-way interaction effects;
131234 is the coefficient of four-way interaction effect; and
8

is the error variable;

The experimental design for ANOVA studies is shown in Table 4. Table 4 lists all the 16
experiments required in a 24 full factorial design. The four independent variables (CLint_s,
Ka_s, ICso and Y) were set at two levels each (60% CV and 30% CV). ANOVA was used
to determine the significance of each of the four independent variables, two-way, threeway interactions and four-way interactions. ANOVA procedures on the response
parameter (INR) were performed using Minitab®software package.
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3.RESULTS
3.1. Variability in PK parameters:
3.1.1. Effect of variability in CLint_s:
The effect of 6 levels of interindividual variability (10, 20, 30, 40, 50 and 60 % CV) in
CLint_s on variability in steady state PK response (Cs) and PD response (INR) was studied
with 7 mg warfarin dose. The model was set to steady state conditions when variability
was added. Table 2 and 3 show the results for variability in Cs and INR, respectively.
The manner in which variability in CLint_S affects Cs and INR are shown in Figure 2 and
3, respectively. There was an approximately linear relationship between the variability in
CLint_s and the PK & PD responses up to about 40 % CV in CLint_S· Of these responses
up to 30 % CV, the variability in CLint_s produced approximately equal variability in Cs
and slightly less in INR. At 50 % or greater variability in CLint_s, the variability in Cs and
INR was found to increase by greater than two fold of that considered in CLint_S· From
equation 2, it can be observed that the hepatic clearance becomes more sensitive as
CLint_s increases and therefore we see higher variability in PK and PD responses. At the
maximum variability (60 % CV) in CLint_s, the observed variability in INR and Cs was
approximately 120 and 163 %, respectively.

3.1.2. Effect of interindividual variability in Ka_sl[P]:
From equation 4, it can be seen that the effect of Ka_s and [P] on fu are similar. In
simulations, it was found that similar variability in Ka_s and [P] produce same variability
on response values (data not shown). As a result, in this study the effect of variability in
only one of these parameters was studied.
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Computer simulations were carried with the fixed dose of 7 mg warfarin and dosing
interval of 24 hours. The effect of interindividual variability in the Ka_s was translated to
changes in steady state Cs and INR (at 480 hours). The results of these simulations are
shown in Table 2 and 3. Figure 2 & 3 represents the effect of the variability in Ka_s as the
function of % CV in PK and PD responses. The relationship between the variability in
Ka_s and the variability in drug's PK and PD responses were found to be linear. Over the
entire range of variability studied, the variability in Cs and INR was found to be less than
that considered in Ka_S· As seen in Figure 2 and 3, the variability in the Ka_s produced
small changes in steady state Cs and INR compared to that due to the variability in
CLint_S· For example, with 60 % CV in Ka_s produced 59.3 and 42.8 % CV in steady
state Cs and INR, respectively whereas with 60 % CV in CLint_s produced 163.6 and
153.6 % CV in steady state Cs and INR, respectively

3.1.3. Effect of interindividual variability in combined PK parameters:

After the effect of variability in individual PK parameters was studied separately,
computer simulations were performed to study the combined effect of interindividual
variability in CLint_S and Ka_s on steady state Cs and INR. Interindividual variability
model as shown in Figure 1c & 1d were used to facilitate the same amount of variability
in both the PK parameters at the same time. Table 2 & 3 show the results for the effect of
interindividual variability in combined PK on the variability in Cs and INR. Figure 2 & 3
represents the effect of variability in combined PK as the function of % CV in Cs and
INR, respectively. From Table 2 & 3, and in agreement with the individual parameter
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studies, both PK parameters when considered together produced less variability in INR
than in Cs. Additionally, although the variability in PK parameters when combined
produced higher amount of variability in Cs and INR than compared to that due to
variability in individual PK parameters, the combination was less than additive(Figure 2
& 3). For example, 40% CV in combined PK parameters resulted 71.2 & 74.8 % CV in

Cs and INR, respectively; 40 % CV in CLint_s resulted 52.2 & 46.5 % CV in Cs and INR,
respectively; and 40 % CV in Ka_s resulted 40.3 & 28.6 % CV in Cs and INR,
respectively

3.2. Variability in PD parameters:
3.2.1. Effect of interindividual variability in IC 50 :

The effect of interindividual variability in IC 5oon steady state INR was studied at 6 levels
of interindividual variability (10, 20, 30, 40, 50 and 60 % CV). Simulation results for
variability in IC 5o when fixed dose of 7 mg warfarin was used are shown in Table 3.
Figure 3 represents the effect of variability in IC 5o as a function of% CV in INR. From
Figure 3, it can be inferred that there is an approximately linear relationship between the
variability in ICso and the INR up to 30 % CV. In this range, the variability in INR was
found to be slightly less than that considered in IC 5o. At 40 % or higher variability in
ICso, the variability in INR was found to be greater than that considered in IC 50 . For
example, 20 % CV in ICso produced 14.2 % CV in INR whereas 60 % CV in IC 50
produced approximately 151 % CV, which is 2.5 times the variability of that considered
in the IC 5o.
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3.2.2. Effect of interindividual variability in Sigmoidicity:

Simulation studies were carried out with the fixed dose of 7 mg warfarin and the
variability in Y was translated to variability in INR. The results of these simulations are
given in Table 3. The relationship between variability in Y and resulting variability in INR
is shown in Figure 3. Over the entire range of variability studied, the resulting variability
in INR was found to be much less than that considered in the parameter. For example
with 60 % CV in the Y, the resulting variability in INR was found to be 1/6 times of that
considered in Y. However, it is unlikely that this magnitude of variability in INR is
clinically significant. Comparing the variability curves for IC 5o & Yin Figure 3, it can be
concluded that the INR is less sensitive to the variability in Y than to the variability in
IC 50 or any of the PK parameters studied.

3.2.3. Effect of interindividual variability in combined PD parameters:

After the effect of variability in individual PD parameters was studied separately, the
combined effect of interindividual variability in both IC 5o and Yon steady state INR was
studied at 6 levels of variability (10, 20, 30, 40, 50 and 60 % CV). Proportional error
model (shown in Figure ld & le) was used to facilitate the same amount of variability in
both the PD parameters at the same time. The results of these simulation studies are
shown in Table 3. The relationship between the combined PD variability and the
variability in INR is shown in Figure 3. Over the entire range of variability studied, the
relationship between combined PD variability and INR was found to be approximately
linear up to 30 % CV. In this range except with 10 % CV, the variability in drug response
was found to be slightly more than that considered in the PD parameters alone. The
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variability in INR due to combined PD was found to be greater than the sum of variability
in INR due to individual PD parameters. At 40 % or greater variability, the drug response
becomes more sensitive to the changes in PD parameters and we see steep increase in the
variability curve (Figure 3). For example, with 10 % variability in combined PD, the
variability in INR was found to be 6.8 % whereas with 60 % CV in combined PD, the
resulting variability in INR was found to be approximately 2.8 folds of that considered in
the parameters. The variability in INR was found to be higher due to combined PD than
that due to combined PK.

3.3. Effect of combined PK and PD variability:

Computer simulations were carried to determine the effect of variability in combined PK
and PD parameters on the drug response. The results of these simulations are given in
Table 3 and Figure 3. Variability in PK & PD parameters when considered together
produced higher amount of variability in INR than that produced due to variability in
individual parameters or combined PK or combined PD parameters, but less than the
sum of variability in INR due to individual PK & PD parameters.
There were a number of occasions in which a simulation yielded INR value that was too
large. Such simulations were terminated and excluded from the study. Essentially with 60
% CV in combined PK and PD parameters could not be studied because the simulation

was unsuccessfully terminated due to division by zero or a value that has become too
large to represent <56>.

3.4. Variability studies using ANOVA:
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The simulation runs were performed as per the experimental design shown in Table 4.
The distribution of INR values from the simulation runs failed to follow the normality
assumption (Appendix 1). The use of square-root and cubic-root transformations on the
INR values did not improved the normality. However, a natural logarithmic
transformation of the INR values greatly improved the normality distribution (Appendix
2). Therefore, statistical analysis using AVOVA method was performed on the natural
log transformed data to determine the significance of each parameter and their
interaction(s). The results of ANOVA test are summarized in Table 5. These results
indicate that PK parameter (CLint_s) and PD parameter (IC 5o) significantly affect the
variability in INR at level of significance, 0.05. The two-way interaction of PK and PD
parameters, CLint_s & ICso and CLint_s & Y, were also found to significantly affect INR
(P<0.05). None of the three-way and four-way interaction(s) of PK and PD parameters
were found to be significant. Hence, these interactions were combined with error to
increase the power of the test. Main effects and interaction plots further support the
results of ANOVA findings. The main effect of a parameter is referred to be the change
in response produced by a change in the level of the parameter. Figure 4 shows the main
effects plot for Ln(INR) data. As can be seen from this plot, the level of% CV in CLint_s
and IC 50 seemed to affect the INR values significantly. As the level of the CLint_s
changed from 30 % CV to 60 % CV, the variation in the mean response value highly
increased. Similarly in the case of IC 5o, as the level is changed from 30 % CV to 60 %
CV, we see a high increase in the mean response valve. In contrast, the level of% CV in
Ka_s and Y slightly affect the INR and this effect was minimal. Difference in response
between the levels of one parameter is not the same at all levels of the other parameter(s).
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These differences in the response is referred to be interaction and can be studied using
interaction plot. Looking at the interaction plot shown in Figure 5, it can be concluded
that there is an interaction between pairs of various parameters such as CLint_S & IC 5o ,
CLint_S & Y and IC 5o & Ka_s since the lines for these parameters in the plot are intersecting
with each other.

3.5. Effect of intraindividual variability in dose:

The effect of intraindividual variability in dose on variability in Cs and INR was studied
at 3 levels (3, 6 and 10 % CV) using both 7 mg and 9 mg dose of warfarin. Sample and
hold set-up, as shown in Figure lf, was used to cause the dose to change after every 24
hours. The results of dose variability studies with 7 mg and 9 mg dose of warfarin, are
shown in Table 6. Figure 6 & 7 show a three-dimensional bar graph of % CV in dose Vs
% CV in INR with 7 mg and 9 mg doses of warfarin, respectively. Each bar in the Figure

6 & 7 represent the magnitude of variability in PK/PD response at a given amount of
variability in the dose. It can be seen in Figure 6 and 7 that variability in dose produced
approximately equal variability in PK response (Cs). In contrast, the INR appears to be
less sensitive to changes in the dose since the variability in the dose was associated with
lower variability in INR. For example, with the maximum variability (10% CV) in 7 mg
& 9 mg dose resulted 10.06 & 10.38 % CV in Cs and 6.01 & 7.40 % CV in INR,

respectively. Variability in PK and PD responses were found to increase with the increase
in the degree of variability in dose. Over the entire range of variability studied, the
variability in dose produced approximately the same amount of variability in drug's PK
response and slightly less variability in drug's PD response. For example, with 6 % CV in
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7 mg warfarin essentially resulted 10.06 & 6.01 % CV in Cs and INR, respectively.
Similarly, with 6 % CV in 9 mg warfarin dose essentially resulted 10.38 & 7.40 % CV in
Cs and INR, respectively. These differences in PK and PD responses may be attributed to
their non-linear relationship.
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4. DISCUSSION

Warfarin, like all the 4-hydroxycoumarin compounds, has an asymmetric carbon atom.
The clinically available warfarin preparations consists of a racemic mixture of equal
amounts of two distinct S- and R-enantiomers, the former being 3 to 6 times more potent
as anticoagulant
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Hence, variability in warfarin responses most likely arises from

variability associated with S-enantiomer. Therefore in this study, we have considered
only the effects of S-enantiomer on warfarin PK and PD responses.

Warfarin has well established PK-PD relationship, narrow therapeutic range and large
PK/PD variability making it a ideal candidate to study the impact of various sources of
variability on the dose-response relationship. In understanding complete dose-response
relationship for drugs like warfarin, an integrated approach involving combined PK and
PD modelling has proved tremendously helpful

6 7
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Hence, this study has attempted to

describe the relationships between the PK, the PD and response to warfarin by
developing an integrated PK-PD model.

The integrated PK-PD model (Figure la & lb) used in this study is based on individual
PK and PD models derived from plasma concentration and response data, respectively <6•
7
)_

This model was developed based on the idea that a thorough understanding of the

impact of variability from a source needed to be based on a complete and integrated PKPD model. The model uses additional component to report the anticoagulant response of
warfarin in terms of INR (Figure 1b), which now has globally become the standard way
of assessing warfarin response
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Previously, there have been no published studies that
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have used computer simulations and an integrated PK-PD model to predict the relative
impact of different sources of variability on warfarin response. Vadher et al. developed a
computerized PK-PD model of the time course of warfarin action with bayesian
parameter estimates and used this model to retrospectively predict the daily INR and
maintenance dose during the initiation of warfarin therapy <57 l.

The operation of integrated PK-PD model in this study was validated by performing the
run without any variability and evaluating the responses to ensure that they agreed with
values calculated from basic PK and PD equations. The operation of error models were
checked by collecting the parameter, which had an error model, and ensuring that the
variability matched that of the model input.

Clinically, warfarin experiences a poor correlation between dose and response, primarily
due to its complex pharmacology and wide inter- and intra-individual variation in doseresponse relationship. Investigations have shown that variation in anticoagulant response
of warfarin occur due to interindividual variability in hepatic clearance <6• 18• 49• 58l, total
protein concentration <29l, protein binding affinity <59l, potency (6) and sigmoidicity
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this study, a pharmacostatistical model(s) was used to provide theoretical evaluation of
the relative impact of these sources of variability on warfarin response.

In the first part of the simulation study, variability was considered in each of the PK and
PD parameters separately and their relative impact on variability in warfarin response
was determined. In the second part of the simulation study, variability in combined PK
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parameters, combined PD parameters, combined PK and PD parameters were considered

(
and their impact on variability in warfarin response was investigated. Finally, the relative
impact of intraindividual variability in the dose on the variability in the warfarin response
was studied.

The simulation studies were conducted using a dose of 7 mg daily since in the PK-PD
model this dose resulted an INR of 2.2, which is at the lower end of therapeutic range of
warfarin. This dose is comparitively higher than that used clinically and this is probably
because the PK and PD parameter values used in this study were derived from healthy,
young volunteers. And the dose of 9 mg daily gave an INR of 2.7, which is at the upper
end of the therapeutic range, and was used in the dose variability study because of the
non-linear PD model.

PK variability was studied by varymg CLint_S and Ka_S· The value of volume of
distribution was kept constant throughout the simulation studies because the variability in
this parameter was reported to be less important <6>.

CLint_s was studied because it is important parameter that affects clearance and several
studies have demonstrated clinically significant outcomes when this parameter changes <6•
18

>. As seen in equation 5, clearance which in itself is critical in determining the steady

state plasma concentration.
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The variability in CLint_S occurs due to differences in the activity of S-warfarin
metabolizing enzyme system. There are several well-established PK drug interactions
with warfarin <60). Many of these drug interactions involve the induction or inhibition of
the cytochrome P450 enzymes with associated reduced or increased anticoagulant effects,
respectively. Interaction of warfarin with phenylbutazone and metronidazole results in
potentiation of anticoagulant effect mainly due to inhibition of the cytochrome P450
isoform <60). The interaction of warfarin with carbamazepine, phenobarbital, phenytoin
and rifampin results in decrease of anticoagulant effect because of the enzyme induction.
William et al. reported marked interindividual differences in the rate of metabolism of
oral anticoagulants in man
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Bowles
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and Gurwitz et al.
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conducted studies to

determine the effect of age on the anticoagulant response of warfarin and reported that
elderly people show an exaggerated anticoagulant response to warfarin, possibly because
of the decrease in clearance with age.

Chan et al. reported 31 % CV in hepatic clearance of S-warfarin (6). Routledge et al.
concluded 40 % CV in total clearance of warfarin
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Based on this information, the

effect of interindividual variability in CLint_s was studied from 10 to 60 % CV (Figure 3
& 4). The statistical analysis of computer-simulated data using ANOVA concluded that

the variability in CLint s alone or in combination with IC 5o/Y are significant (P<0.05) and
need to be carefully considered to perform dose optimization in warfarin therapy and use
the drug safely.
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Warfarin is highly protein bound (in excess of 99%) and the anticoagulant effect is
caused by the very small fraction of the drug that is free. Albumin acts as the storage
depot for warfarin. As indicated in section 1.5.1 of this thesis, the variation in P and Ka_s
can occur due to various physiologic and pathologic conditions. Under these
circumstances clinically significant changes in the anticoagulant response of warfarin
have been observed
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Drugs that can displace the albumin will also in theory increase

the action of warfarin. However, this effect may be counteracted by more rapid
elimination of the drug <59>. Interestingly, although variability in protein binding produced
almost equivalent variability in Cs (Table 2), this source of variability had little impact on
INR, especially in comparison to variability in CLint_s (Figure 3). The statistical analysis
of the computer-simulated data using ANOV A indicated that Ka_s do not significantly
affect the warfarin response (P<0.05).

The relationship between Cs and PCA is given by (Pitsiu et al 1993)
PCA =

[

100 I (1 + (C// ICsoy)) ]

(16)

The relationship between the PD parameters and the INR can be derived by subtituting
the equation (12) and (16) in equation (13):
INR = (1.001 + (0.355

* C// IC 50y) ]1s1

(17)

Thus, the warfarin response in terms of INR is dependent on PD parameters such as IC 50
and Y. IC 50 and Y was reported to vary from individual to individual (6, 1>. Therefore, the
impact of variability in these PD parameters on INR was studied.
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Potency (IC 50) represents the concentration of drug that produces 50% of the maximum

I

effect. It explains the differences in sensitivity of the drug to the receptors. As the IC 50
increases, the drug gets less potent and a smaller response is achieved from a given dose.
This condition is referred to as warfarin resistance. In contrast as the IC 50 decreases, the
drug gets more potent and a higher response is achieved from a given dose. Such
condition is usually termed as warfarin sensitivity. In the literature several studies have
reported about the warfarin resistance and sensitivity. In most cases the exact mechanism
for these changes has not been identified. However, possible explanations for such
changes in IC 50 of warfarin include altered receptor affinity, noncompliance, exogenous
consumption of vitamin K, hereditary reasons, laboratory error and concurrent ingestion
of warfarin with nutritional supplements containing vitamin K are known to decrease
warfarin's effects. In early 1985, Alving et al reported that 57-year-old black women and
her family developed warfarin resistance due to hereditary reasons that altered PDs of
warfarin

43
< )_

Warfarin resistance associated with infusion of high doses of lipids such as

propofol containing 10 % soybean oil as an emulsified preparation was investigated by
MacLaren et al. and concluded that lipid emulsions may interfere pharmacodynamically
with warfarin activity by enhancing the production of clotting factors, facilitating platelet
aggregation or may facilitate warfarin binding to albumin <62>.

The amount of interindividual variability in IC 5o was chosen based on the values reported
in the literature. The population analysis performed by Chan et al. using NONMEM
approach showed that IC 50 of unbound fraction of S-warfarin varied by 58 % CV <6>. In
this study, the effect of interindividual variability in IC 50 on warfarin response was
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demonstrated from 10 % to 60 % CV (Figure 3). Analysis of the computer-simulated data
suggests that warfarin response is highly sensitive to variability in ICso alone or in
combination with CLint_s (Table 5).

Sigmoidicity refers to the slope value for the relationship between the drug concentration
and pharmacological effects. Interindividual variability in Y for warfarin is reported in the
literature (6, 7). It is difficult to explain the reason for the variation in this slope parameter,
as this parameter has no clear physiological interpretation. However, the variability in Y is
of substantial clinical significance. Individuals having low Y value (steeper slope) for the
relationship between drug concentration and the anticoagulant effect will be very
sensitive to small changes in drug concentration and becomes difficult to maintain their
INR values in the therapeutic range. On the contrary, individuals with higher Y value for
drug concentration-effect relationship will not be much sensitive to small changes in drug
concentration. Chan et al. (6) reported 25 % CV and Pitsiu et al. C7) reported 42 % CV in Y.
However, this study found that variability in Y, when varied at various levels from 10 %
to 60 % CV (Figure 3), had little impact on warfarin response.

Variability in dose results due to weight variation, assay error, flow properties of the
tablet blend and various formulation processes. The United States Pharmacopoeia allows
up to 5 % variability in the dose of warfarin
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Based on this information, the

intraindividual variability in the dose was studied at three levels (3, 6 and 10 % CV).
Variability in the dose resulted in almost the same amount of variability in Cs and
slightly more than half in INR. Thus, the PK and PD responses appear to be less sensitive
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to the changes in dose. As seen from Figure 8, it can be concluded that the dose of
warfarin when used at the lower end and higher end of the therapeutic range does not
produce significant difference in the PK & PD responses.

In conclusion, the computer simulations in this study have demonstrated that CLint_S and
IC 50 are most influencing parameters that affect the dose-response relationship than the
other parameters studied. Therefore, it is important to consider the influence of variability
in these parameters in optimizing the dose and thereby achieving the desired therapeutic
effect in patients who have the history of hepatic impairment, warfarin resistance and
sensitivity.
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CONCLUSIONS

•

An integrated PK-PD model was successfully developed for warfarin usmg
STELLA® .

•

This study demonstrated the importance of considering PD model along with PK
model to understand the dose-response relationship for warfarin .

•

Computer simulations were performed using a pharmacostatistical PK-PD model to
understand the manner in which various PK and PD parameters affect the doseconcentration-effect relationship

for

warfarin.

Analysis

of simulation

data

demonstrated that interindividual variability in PK parameter (CLint_s) and PD
parameter (IC 5o) most significantly affect the variability in warfarin response. The
variability in these parameters should be carefully considered in order to use the drug
safely and effectively .

•

Findings from the statistical analysis strongly suggest that CLint_s, IC 50 and the
combination of PK & PD parameters such as CLint_s & ICso and CLint_S & Y
significantly affect the variability in INR (P < 0.05) .

•

The drug response was found to be less sensitive to the intraindividual variability in
dose and interindividual variability in Ka_s and Y.
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Thus, simulation studies usmg STELLA produced sensible results that helps in
understanding the manner in which the variability in various PK and PD parameters
affect the overall dose-response relationship. Such information is important and useful in
optimizing the doses in specific population under risk and uses the drug effectively and
safely. It is to be noted that the conclusions of this study are obviously limited to the
theoretical assumptions considered in the model.
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Table 1 : Population average values of the PK and PD parameters used in the model

Parameter

Mean Value (Input to Model)

PK parameters
Vd_S

11.8 L

Vd_R

10.5 L

CLint_s

59.21 L/h

CLint_R

32.85 L/h

Ka_S

300000 h- 1

Ka_R

246600.49 h- 1

PD parameters
0.394

ICso
CA_nonnal

100

y

1.0

ISI

2.2

~

0.094 h- 1

*For sources of these values see the text.
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Table 2: Effect of interindividual variability in PK parameters on Cs when 7 mg
dose of warfarin was used
% CV in PK
parameter

% CV in Cs due to variability in [n=lOO]

CLint_s

Ka_S

Combined PK

10

10.l

10.3

14.6

20

20.5

20.6

31.3

30

32.9

30.5

50.2

40

52.2

40.3

71.2

50

120.6

49.8

130.5

60

163.6

59.3

200.5

Abbreviations: Clint s =Intrinsic clearance ofS-enantiomer ofwarfarin
K. s-= Protein binding affinity constant of S-enantiomer of warfarin
Cp-= Overall warfarin plasma concentration
Cs = Plasma concentration of S-enantiomer of warfarin
n =Number of study individuals
Combined PK= Variability in Cl; 01_s and K._s
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Table 3: Effect of interindividual variability in PK and PD parameters on INR when 7 mg
dose of warfarin was used
% CV in INR due to variability in [n=lOO]

%CVin
PK/PD
pa ram et
er
Clint_S

Ka_S

Com binedPK

ICso

Combi- Combined
nedPD PK&PD

y

10

6.8

7.1

9.0

6.8

1.6

6.2

12.9

20

14.1

14.3

23.5

14.2

3.2

28.5

31.6

30

24.4

21.4

42.5

24.5

4.8

48.7

63.7

40

46.5

28.6

74.8

46.7

6.5

87.5

121.7

50

119.1

35.7

122.6

117.9

8.2

143.2

157.8

60

153.6

42.8

161 .2

151.5

10.1

166.l

NIA

Abbreviations: Clint s = Intrinsic clearance of S-enantiomer of warfarin
K. ; = Protein binding affinity constant of S-enantiomer of warfarin
IC~0 = Potency of S-enantiomer of warfarin
Y = Sigmoidicity
INR = International Normalized Ratio
n = Number of study individuals
NIA = Not Applicable
Combined PK = Variability in Clint s and Ka s
Combined PD = Variability in IC 50-and Y Combined PK & PD = Variability in Clint_s , Ka_s, ICso and Y
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Table 4: Experimental design for ANOVA test

(
% CV Parameter
ICso
Ka_S

Run
Number

CLint_s

1

-

-

-

-

2

-

+

-

-

3

-

-

+

-

4

-

+

+

-

5

+

-

-

-

6

+

+

-

-

7

+

-

+

-

8

+

+

+

-

9

-

-

-

+

10

-

+

-

+

11

-

-

+

+

12

-

+

+

+

13

+

-

-

+

14

+

+

-

+

15

+

-

+

+

16

+

+

+

+

i

Abbreviations: (-)means 30% CV and(+) means 60% CV
Cl; 01 s = Intrinsic clearance of S-enantiomer of warfarin
K. 5-= Protein binding affinity constant ofS-enantiomer ofwarfarin
IC~0 = Plasma concentration of S-warfarin that produces 50% inhibition
of clotting factor synthesis
Y = Sigmoidicity
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Table 5: Analysis of variance of effect of variability in PK and PD parameters on
{

Ln(INR)

ss+

ss+

Adj MSt

F

p*

2.8096

2.8096

3.41

0.060

0.7613

0.8196

0.8196

1.00

0.316

1

3.7037

3.4390

3.4390

4.18

0.041

y

1

0.1913

0.2329

0.2329

0.28

0.590

CLint_s*Ka_s

1

0.3629

0.5025

0.5025

0.61

0.480

CLint_s*ICso

1

3.1134

3.2090

3.2090

3.90

0.049

CLint_s*y

1

3.2399

3.2149

3.2149

3.91

0.047

Ka_s*ICso

1

0.5449

0.5997

0.5997

0.73

0.418

Ka_s*y

1

0.0358

0.0417

0.0417

0.05

0.832

1

0.0516

0.0517

0.0517

0.06

0.802

1495

1231.2517

1231.2517

0.8236

1505

1246.4681

Source

DF•

Seq

CLint_s

1

3.2115

Ka_S

1

ICso

ICso*Y

Error
Total

Adj

A OF = Degrees of Freedom

+ Seq SS = Sequential Sum of Squares
+Adj SS = Adjusted Sum of Squares
t Adj MS = Adjusted Mean Square
* p < 0.06
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Table 6: Effect of intraindividual variability in dose on variability in Cs and JNR.

(

% CV in [n=2000]

% CV in Dose

Cs

INR

3

3.10

1.77

6

5.93

3.55

10

10.06

6.01

3

2.93

2.21

6

5.87

4.34

10

10.38

7.40

With Dose 7mg

With Dose 9mg

(

Abbreviations: CV = Coefficient of Variation
INR = International Normalized Ratio
n = Number of study individuals
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Figure 1: Schematic diagram showing various models in STELLA®
(a) Pharmacokinetic model
(b) Pharmacodynamic model
(c) Interindividual variability in CLint_s
(d) Interindividual variability in Ka_s
(e) Interindividual Variability in IC 50
(f) Interindividual variability in Y
(g) Intraindividual variability in dose
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Figure 2: Effect of interindividual variability in PK parameters as the function of
coefficient of variation (CV) in Cs when 7 mg dose ofwarfarin was used.
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Figure 3: Effect of interindividual variability in PK and PD parameters as the function of
coefficient of variation (CV) in INR when 7 mg dose of warfarin was used
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Figure 4: Main effects plot ofLn(INR) data.
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Figure 5: Interaction plot of Ln(INR) data.
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Figure 6: Effect of intraindividual variability in dose (7 mg) as the function of coefficient
of variation (CV) in Cs and INR.
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Figure 7: Effect of intraindividual variability in dose (9 mg) as the function of coefficient
of variation (CV) in Cs and INR.
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Figure 8: Effect of intraindividual variability in dose as the function of coefficient of
variation (CV) in INR with dose of 7 mg and 9 mg warfarin.
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Appendix 1: Model adequacy check for INR data using ANOV A test.

76

Normal Probability Plot of the Residuals

(

(response is INR)

--··-·.

2

. . ...

0
-1

-2
-3

100

0

200

400

300

500

600

Residual

Residuals Versus the Order of the Data
(response is INR)

600
500

400

"iii

:J

1J

'iii

&

300

..

200
100

. "':be

• •

....

0

I

200

.
... . . .+r ......-a....
..
:•,;s ·,

400

•I

r

600

,,•,

800

1

1000

1200

1400

Observation Order

Residuals Versus the Fitted Values
(response is INR)

600
500

400

"iii

:J

1J

'iii

&

300

200

.

100
0

•

•

•

•

I

-1----1-1-----1--i ----•-i--l-4----l--i-----l-t----·--3

6

8

10

11

Fitted Value

77

12

13

Residuals Versus Clint_S
(response is

600-

I~)

•

500400-

I
100-

o-

:

_j ______ ------------------------------------------------ _J __
-1

T
0

T
1

Clint_S

Residuals Versus Ka_S
(response is INR)

600-

500400(ij
:J
"O

&

300200-

_

1:~ i _____ ---------------------- -------------- --------__ j _
-1

T

1

0

Ka_S

Residuals Versus IC50
(response is

400"""

I~)

•

..
1:: .1_----------------------------------------------------__ j_
I

-1

0

ICSO

78
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Appendix 2: Model adequacy check for Ln(INR) data using ANOV A test.
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Mean:

0.0000000

Stllev:

0.904193

Barlett's test for CL;nt_s:
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Barlett's test forIC 50 :
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